Luis Bujanda

Infection with the bacterium Helicobacter pylori is a known risk factor for stomach cancer. Its link to colorectal cancer, however, remains an unconfirmed hypothesis. An international team has reviewed 43 studies on this subject and found that 22 per cent of colorectal cancer cases could potentially be linked to this infection, although when they selected the 14 most reliable studies, the figure fell to 12 per cent. According to the authors, exposure to Helicobacter pylori could be contributing significantly to the number of cases of colon cancer worldwide, but they point out that their study is only exploratory and that more robust research, such as clinical trials, is needed to establish a causal link. The results have been published in eGastroenterology.

Several recent studies had concluded that the risk of gastric cancer doubled with the use of drugs such as omeprazole – proton pump inhibitors. A new study published in The BMJ states that there is no association between prolonged use of these drugs and the risk of gastric adenocarcinoma. The research used prospective data from registries in Denmark, Finland, Iceland, Norway, and Sweden between 1994 and 2020. The study included more than 17,000 patients with gastric adenocarcinoma (other than cardia cancer) who had been exposed to these drugs for more than one year.

Research estimates that 15.6 million people born between 2008 and 2017 worldwide will develop gastric cancer at some point in their lives if current trends continue. In Spain, there would be 58,641 cases, or 1.24% of people in this age group. The team used data on gastric cancer from 185 countries in 2022 combined with mortality projections based on United Nations demographic data. The estimates, published in the journal Nature Medicine, show that 76% of cases could be attributed to Helicobacter pylori, a common bacterium found in the stomach.

The European Medicines Agency (EMA) safety committee (PRAC) has recommended a change to the information on codeine-ibuprofen combination medicines to include "a warning about serious harm, including death, especially when taken for prolonged periods at higher than recommended doses". The PRAC reviewed several cases of renal, gastrointestinal and metabolic toxicity that had been reported in association with cases of abuse and dependence on these drugs.